SMS Pharmaceuticals Delivers Strong FY26 Results, Profit Soars 47%

FY26 Revenue: ₹887 crore
PAT: ₹102 crore

Reader Takeaway: Robust profit growth driven by operational efficiency, but geopolitical risks and client concentration remain concerns.

What just happened

SMS Pharmaceuticals Limited announced its financial results for the fiscal year 2026, reporting a significant 13% increase in total revenue to ₹887 crore and a substantial 47% rise in Net Profit After Tax (PAT) to ₹102 crore. The company also provided a revenue guidance of 15% growth for FY27. Full-year EBITDA stood at ₹171 crore, marking a 23% increase and improving margins to 20%.

Why this matters

This strong financial performance indicates improved operational leverage and successful cost management strategies. The planned capacity expansion and guidance for continued growth signal positive momentum. However, the company noted that geopolitical developments impacted raw material costs in Q4 FY26, highlighting sensitivity to external factors.

The backstory

In FY26, SMS Pharmaceuticals saw its revenue climb due to strong performance in the anti-inflammatory and ARV segments. The company's focus on backward integration, including projects like ibuprofen, has helped improve its product mix and control costs, leading to enhanced EBITDA margins.

What changes now

The company is undertaking a brownfield expansion to boost its installed capacity from 500 metric tons/month to 800 metric tons/month, expected to be completed by March 2027. This expansion aims to support future volume growth, with incremental revenue contribution expected from FY28. The company also filed 12 Drug Master Files (DMFs) and CEPS in FY26.

Risks to watch

A key concern is revenue concentration, with 28% of revenue coming from a single customer. Additionally, geopolitical volatility in the Middle East could continue to affect solvent costs and logistics, impacting raw material consumption and margins. Management aims for a medium-term EBITDA margin of 22%.

Peer comparison

While specific peer results are not detailed in the filing, SMS Pharmaceuticals' growth and margin improvement in FY26, alongside its capacity expansion plans, position it for competitive performance in the pharmaceutical ingredients sector.

Context metrics (time-bound)

• FY26 Revenue: ₹887 crore (up 13% YoY)
• FY26 PAT: ₹102 crore (up 47% YoY)
• FY26 EBITDA Margin: 20%
• Q4 FY26 EBITDA Margin: 17%
• Capacity Expansion: To 800 MT/month by March 2027.
• FY27 Revenue Guidance: 15% growth.

What to track next

Investors will be watching the progress of the brownfield expansion project and its timely completion. The company's ability to manage the 28% revenue concentration from its largest customer and navigate potential fluctuations in raw material costs due to geopolitical events will be crucial.